C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Their Degronimid platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
01/07/16	$73,000,000	Series A	Cobro Ventures Cormorant Asset Management EG Capital Group Novartis Venture Funds Roche Venture Fund The Kraft Group	undisclosed
06/16/20	$170,000,000	Series B	3E Bioventures Adage Capital Management Axil Capital Bain Capital Life Sciences Cobro Ventures Commodore Capital HBM Healthcare Investments Lightchain Capital Logos Capital Mizuho Securities Principal Investment Nextech Invest Perceptive Advisors	undisclosed